Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

1.5K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.7K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.6K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Videos

Montelukast

A Markham1, D Faulds

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Montelukast effectively treats asthma by blocking leukotriene D4 (LTD4) receptors, reducing airway inflammation and symptoms. Clinical trials show montelukast at 10 mg daily is optimal for managing asthma in adults and children.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Trials

Background:

  • Asthma is a chronic respiratory disease characterized by airway inflammation and hyperresponsiveness.
  • Leukotriene D4 (LTD4) is a key mediator in the inflammatory cascade of asthma.
  • Selective LTD4 receptor antagonists offer a targeted therapeutic approach for asthma management.

Purpose of the Study:

  • To evaluate the efficacy and optimal dosage of montelukast in patients with asthma.
  • To compare montelukast with placebo and beclomethasone in asthma control.
  • To assess the potential for corticosteroid dose reduction in asthma patients treated with montelukast.

Main Methods:

  • Montelukast's effect on LTD4-induced bronchoconstriction was assessed.
  • Randomized, double-blind, placebo-controlled trials were conducted to evaluate montelukast's efficacy.
  • Open-label extension studies compared montelukast with beclomethasone.
  • Studies included adult and childhood asthma populations, assessing various dosages.

Main Results:

  • Montelukast (5-250 mg/day) attenuated LTD4-induced bronchoconstriction.
  • A dosage of 10 mg/day significantly reduced early and late airway responses to allergens.
  • Montelukast 10 mg/day demonstrated superior asthma control compared to placebo over 3 months.
  • In a 9-month trial, montelukast 10 mg/day showed comparable efficacy to beclomethasone in reducing symptoms and beta-agonist use.
  • Montelukast 10 mg/day enabled significant corticosteroid tapering in stable asthma patients.
  • Montelukast 5 mg/day was effective in childhood asthma.
  • Tolerability was similar to placebo, with headache being the most common adverse event.

Conclusions:

  • Montelukast is an effective treatment for asthma, offering significant benefits in symptom control and airway response.
  • The optimal dose for montelukast in managing asthma is 10 mg/day.
  • Montelukast provides a valuable therapeutic option, including the potential to reduce corticosteroid dependence in asthma management.
  • Montelukast demonstrates a favorable safety profile comparable to placebo.